Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase

Proceedings of the National Academy of Sciences of the United States of America
Katie J AldredNeil Osheroff

Abstract

Mycobacterium tuberculosis is a significant source of global morbidity and mortality. Moxifloxacin and other fluoroquinolones are important therapeutic agents for the treatment of tuberculosis, particularly multidrug-resistant infections. To guide the development of new quinolone-based agents, it is critical to understand the basis of drug action against M. tuberculosis gyrase and how mutations in the enzyme cause resistance. Therefore, we characterized interactions of fluoroquinolones and related drugs with WT gyrase and enzymes carrying mutations at GyrA(A90) and GyrA(D94). M. tuberculosis gyrase lacks a conserved serine that anchors a water-metal ion bridge that is critical for quinolone interactions with other bacterial type II topoisomerases. Despite the fact that the serine is replaced by an alanine (i.e., GyrA(A90)) in M. tuberculosis gyrase, the bridge still forms and plays a functional role in mediating quinolone-gyrase interactions. Clinically relevant mutations at GyrA(A90) and GyrA(D94) cause quinolone resistance by disrupting the bridge-enzyme interaction, thereby decreasing drug affinity. Fluoroquinolone activity against WT and resistant enzymes is enhanced by the introduction of specific groups at the C7 and C8 p...Continue Reading

References

Jul 4, 1998·The Journal of Biological Chemistry·J M Fortune, N Osheroff
Sep 28, 1998·Biochimica Et Biophysica Acta·D C Hooper
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K R Hande
Dec 20, 1999·Drugs·D C Hooper
Mar 16, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D C Hooper
Mar 20, 2001·Current Pharmaceutical Design·V E Anderson, N Osheroff
Jun 8, 2001·Annual Review of Biochemistry·J J Champoux
Oct 9, 2002·Microbiology·Jean-Christophe CamusStewart T Cole
Jun 9, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vincent T Andriole
Aug 17, 2005·Current Medicinal Chemistry. Anti-cancer Agents·E L Baldwin, N Osheroff
Aug 1, 2006·Biochemical and Biophysical Research Communications·Alexandra AubryEmmanuelle Cambau
Oct 3, 2006·The European Respiratory Journal·G B MiglioriM C Raviglione
Aug 29, 2007·Antimicrobial Agents and Chemotherapy·Karl DrlicaXilin Zhao
Sep 4, 2008·Antimicrobial Agents and Chemotherapy·Nadezhda GermanRobert J Kerns
Oct 8, 2008·Antimicrobial Agents and Chemotherapy·Sonia K Morgan-LinnellLynn Zechiedrich
Apr 8, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard LongThomas Marrie
Jun 2, 2009·American Journal of Respiratory and Critical Care Medicine·Rose A DevasiaTimothy R Sterling
Sep 15, 2009·Current Topics in Medicinal Chemistry·Karl DrlicaXilin Zhao
Apr 21, 2010·Antimicrobial Agents and Chemotherapy·Lisa M OppegardHiroshi Hiasa
Jun 11, 2010·Chemistry & Biology·Yves PommierChristophe Marchand
Aug 31, 2010·Nature Structural & Molecular Biology·Alexandre WohlkonigBenjamin D Bax
Jan 18, 2011·International Journal of Antimicrobial Agents·Sandhya Bansal, Vibha Tandon
Nov 12, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ronald F GrossmanFrancesco Blasi
Jan 15, 2014·Antimicrobial Agents and Chemotherapy·Rupesh KumarValakunja Nagaraja
Mar 1, 2014·Biochemistry·Katie J AldredNeil Osheroff
Jan 23, 2016·Proceedings of the National Academy of Sciences of the United States of America·Tim R BlowerJames M Berger

❮ Previous
Next ❯

Citations

Jan 23, 2016·Proceedings of the National Academy of Sciences of the United States of America·Tim R BlowerJames M Berger
Jun 11, 2016·Future Medicinal Chemistry·Yuk-Ching Tse-Dinh
Jan 11, 2017·Journal of Biomolecular Structure & Dynamics·Bharati PandeyAbhinav Grover
Nov 9, 2016·Journal of Drug Targeting·Nzungize LambertJianping Xie
Mar 2, 2017·Journal of Cellular Biochemistry·Bharati PandeyAbhinav Grover
Oct 27, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jong H KimLuisa W Cheng
Oct 5, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Erika KappJacques Joubert
Jun 15, 2016·Antimicrobial Agents and Chemotherapy·Areeya DisratthakitAngkana Chaiprasert
Sep 19, 2019·Molecular Biology and Evolution·Rhastin A D CastroSebastien Gagneux
Sep 30, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Pravin Kumar SinghAmita Jain
Mar 2, 2019·Antibiotics·Katie J AldredOlivia Voegerl
Sep 22, 2017·Nucleic Acids Research·Rachel E AshleyNeil Osheroff
May 17, 2017·Proceedings of the National Academy of Sciences of the United States of America·Pan F ChanRobert A Stavenger
Oct 22, 2020·Expert Review of Anti-infective Therapy·Karl Drlica, Xilin Zhao
Feb 28, 2021·Chemical Biology & Drug Design·Shahinda S R AlsayedHendra Gunosewoyo
May 1, 2021·Pharmaceutics·Filia StephanieUsman Sumo Friend Tambunan
May 19, 2021·Antimicrobial Agents and Chemotherapy·Dereje Abate NegatuThomas Dick
Sep 19, 2017·Biochemistry·Rachel E AshleyNeil Osheroff
May 11, 2018·ACS Infectious Diseases·Elizabeth G GibsonNeil Osheroff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.